Metastatic Advanced Pancreas Sorafenib

Inclusion Criteria:

* Signed written informed consent prior to beginning protocol specific procedures
* Male or female 18 to 75 years of age
* Diagnosis of histologically confirmed adenocarcinoma of the pancreas
* Locally advanced (non-resectable) or metastatic pancreatic cancer
* Presence of at least one uni-dimensional indicator lesion measurable by CT scan or MRI in not an irradiated area (RECIST criteria)
* Karnofsky performance status of ≥ 70 at study entry
* Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL
* Bilirubin level either normal or \< 1.5 x ULN
* ASAT and ALAT ≤ 2.5 X ULN (≤ 5 x ULN if liver metastasis are present)
* Serum creatinine \< 1.5 x ULN
* Amylase and lipase ≤ 1.5 x the upper limit of normal
* PT or INR and PTT \< 1.5 x upper limit of normal (subjects who receive anti-coagulation treatment with an agent such as warfarin or heparin will be allowed to participate provided that no evidence of underlying abnormality in these parameters exists).
* Effective contraception for both male and female patients if the risk of conception exists

Exclusion Criteria:

* Brain metastases
* Previous chemotherapy for locally advanced or metastatic pancreatic cancer.
* Adjuvant therapy if documented recurrence is within 6 months after the end of adjuvant treatment)
* Radiotherapy within 4 weeks prior to study entry
* Major surgery within 4 weeks of first dose of study drug
* Concurrent chronic systemic immune therapy
* Any investigational agent(s) 4 weeks prior to entry
* Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 6 months
* Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months
* Acute or subacute intestinal occlusion or history of inflammatory bowel disease
* Known grade 3 or 4 allergic reaction to any of the components of the treatment
* Known drug abuse/ alcohol abuse
* Legal incapacity or limited legal capacity
* Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent
* Women who are pregnant or breastfeeding
* Acute or subacute intestinal occlusion
* Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix. (Patients with a previous malignancy but without evidence of disease for ≥ 5 years will be allowed to enter the trial).